Clinical Observation On Shuganlipi Decoction Co-entecavir In Treating Liver Stagnation And Spleen Deficiency Type Chronic Hepatitics B

Purpose:to observe the clinical efficacy of Shuganlipi Decoction Co-entecavir treat liver stagnation and spleen deficiency type chronic hepatitics B.Material and method:60 patients of liver stagnation and spleen deficiency type chronic hepatitis B were collected and then randomly divided into the treatment group with 30 cases and the control group with 30 cases.Patients of the treatment group were treated with entecavir tables,0.5mg/times,1 time/day,meanwhile oral Shuganlipi Decoction,of which 1000 ml water were extracted 300 ml,100ml/times,2 times/day.While patients of the control group were only treated with entecavir tables,0.5mg/times,1 time/day.Both were observed 48 weeks.The main purpose of the study was to observe the clinical efficacy of Shuganlipi Decoction Co-entecavir in treating chronic hepatitis B,and the improving situation of the condition on several biochemical indicators of Liver, the virus index of chronic hepatitis B,antiviral response rates,clinical syndrome and the quality of life.Results:(1)After treatment of 48 weeks,the total effective rate of the treatment group was 90%,while the result of the control group was 76.7%.There was a significant difference between the results of the groups.(2)Comparing the symptom scores between the two groups after 24 weeks of treatment,the result was a significant difference(p<0.05).Comparing the symptom scores between the two groups after 48 weeks of treatment,the result was a significant difference(p<0.05).After 48 weeks of treatment,the total effective rate of symptom in patients of treatment group was 93.3%,while the result of the control group was 83.3%.There was a significant difference between the results of the two groups.(3)After treatment of 48 weeks, comparing the quality scores of life between the two groups,the quality scores of life in treatment group is higher than that in control group,the result was a significant difference(p<0.05).(4)There was a significant difference between the results of the two groups in the levels of ALT and AST after the treatment of 12,24 and 48 weeks(p<0.05). There was a significant difference between the results of the two groups in the levels of TBIL after the treatment of 48 weeks(p<0.05). There was no significant difference between the results of the two groups in the levels of TBIL after both the treatment of 12 and 24 weeks(p<0.05).There was no significant difference between the results of the two groups in the levels of ALB during the whole treatment(p>0.05).(5)After treatment of 48 weeks, comparing HBV-DNA and antiviral response rates between the two groups, there was no significant difference between the results of the two groups(p>0.05).Conclusion: 1、The treatment of using Shuganlipi Decoction Co-entecavir in chronic hepatitics B can obviously improve the clinical effect.Comparing with the treatment of only using entecavir,it works faster in improving the liver function. 2 Comparing with the treatment of only using entecavir in chronic hepatitics B,the treatment of using Shuganlipi Decoction Co-entecavir has unique advantages in improving the clinical symptoms and enhancing the quality of life.